InvestorsHub Logo
Followers 0
Posts 47
Boards Moderated 0
Alias Born 09/27/2017

Re: None

Thursday, 10/19/2017 10:36:00 AM

Thursday, October 19, 2017 10:36:00 AM

Post# of 12137
A reminder:

Kite Pharma completed its BLA submission to the FDA for approval of its

CAR-T axi-cel, previously known as ZUMA-1. It also appealed for priority review, the same status the FDA awarded

to Novartis CTL019. The FDA set an action date of November 29, 2017



18 Oct is much earlier that 29 Nov.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYRX News